{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "FlublokPI",
  "verification_stats": {
    "total_snippets": 3,
    "verified": 3,
    "failed": 0,
    "high_confidence": 3,
    "medium_confidence": 0,
    "low_confidence": 0
  },
  "verified_snippets": [
    {
      "id": 1,
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14 1). The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "relevance_explanation": "This quote directly states that Flublok Quadrivalent was evaluated in a trial (Study 6) against Fluarix Quadrivalent, a standard-dose quadrivalent influenza vaccine, supporting the claim.",
      "verification_status": "verified",
      "confidence": "high",
      "actual_text": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quad rival ent or Comparator (Fluarix Quad rival ent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14 1. The safety analysis population included 4328 Flublok Quad rival ent recipients and 4344 Comparator vaccine recipients.",
      "differences": [
        "Spacing differences in 'Quadrivalent' (appears as 'Quad rival ent' in document)",
        "Missing closing parenthesis in '[see Clinical Studies (14 1)'",
        "Minor punctuation differences (periods, parentheses)",
        "No space after 'Study 6' in quote, but present in document"
      ]
    },
    {
      "id": 2,
      "quote": "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "relevance_explanation": "This quote defines the comparator in the pivotal trial as Fluarix Quadrivalent, confirming that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent.",
      "verification_status": "verified",
      "confidence": "high",
      "actual_text": "Abbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.- licensed quad rival ent inactivatedin\ufb02uenzavaccine, FluarixQuadrivalent, manufactured by GlaxoSmithKline; n=number of in\ufb02uenzacases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "differences": [
        "Spacing differences in abbreviations (e.g., 'reversetranscriptasepolymerasechainreaction' vs 'reverse transcriptase polymerase chain reaction')",
        "Spacing differences in 'U.S.- licensed quad rival ent inactivatedin\ufb02uenzavaccine, FluarixQuadrivalent' vs 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent'",
        "Ligature differences (e.g., 'in\ufb02uenza' vs 'influenza')",
        "Spacing differences in 'number of in\ufb02uenzacases' vs 'number of influenza cases'",
        "Spacing differences in 'FluarixQuadrivalent' vs 'Fluarix Quadrivalent'"
      ]
    },
    {
      "id": 3,
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol-defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 \u2013 [Attack rate Flublok Quadrivalent Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).",
      "relevance_explanation": "This quote describes the design of the pivotal trial (Study 6), showing that Flublok Quadrivalent was directly compared to a comparator vaccine, which is defined elsewhere as Fluarix Quadrivalent.",
      "verification_status": "verified",
      "confidence": "high",
      "actual_text": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol-de\ufb01ned ILI due to any strain of in\ufb02uenza. Attack rates and relative vaccine efficacy (rVE), de\ufb01ned as 1 \u2013 [Attack rate Flublok Quad rival ent Attack Rate Comparator], were calculated for the total efficacy population",
      "differences": [
        "Minor spacing difference in 'Quad rival ent' vs 'Quadrivalent'",
        "Ligature differences: 'de\ufb01ned' vs 'defined', 'in\ufb02uenza' vs 'influenza'",
        "The quote in the document is truncated and does not include '(n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).' portion"
      ]
    }
  ],
  "failed_snippets": [],
  "model_used": "gpt-4.1"
}